Literature DB >> 7866875

Herpes simplex virus vectors for gene therapy.

D S Latchman1.   

Abstract

Herpes simplex virus (HSV) has a number of advantages as a vector for delivering specific genes to the nervous system. These include its large size, wide host range, and its ability to establish long-lived asymptomatic infections in neuronal cells in which a specific region of the viral genome continues to be expressed. Unfortunately, the large size of this virus and difficulty in manipulating it has led to its use as a vector lagging behind that of other, smaller viruses such as the retroviruses. In addition, the virus's ability to replicate lytically in the brain, under some circumstances, causing encephalitis, has led to fears about its potential safety for ultimate use in humans. This review will discuss a number of new approaches that are aimed at rendering simpler the insertion of foreign genes into the virus and making it as safe as possible. Ultimately, these advances offer real hope for the use of HSV vectors in gene therapy procedures.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866875     DOI: 10.1007/bf02824809

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  47 in total

1.  MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-04       Impact factor: 3.616

2.  The octamer-binding protein Oct-2 represses HSV immediate-early genes in cell lines derived from latently infectable sensory neurons.

Authors:  K A Lillycrop; C L Dent; S C Wheatley; M N Beech; N N Ninkina; J N Wood; D S Latchman
Journal:  Neuron       Date:  1991-09       Impact factor: 17.173

3.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence.

Authors:  I MACPHERSON; M STOKER
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

4.  A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

Authors:  A T Dobson; T P Margolis; F Sedarati; J G Stevens; L T Feldman
Journal:  Neuron       Date:  1990-09       Impact factor: 17.173

5.  Herpes simplex virus amplicon: cleavage of concatemeric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence.

Authors:  L P Deiss; N Frenkel
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

6.  Electron microscopy of herpes simplex virus. I. Entry.

Authors:  C Morgan; H M Rose; B Mednis
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

7.  Herpesvirus infections of the human central nervous system.

Authors:  L C Olson; E L Buescher; M S Artenstein; P D Parkman
Journal:  N Engl J Med       Date:  1967-12-14       Impact factor: 91.245

8.  Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription.

Authors:  M E Campbell; J W Palfreyman; C M Preston
Journal:  J Mol Biol       Date:  1984-11-25       Impact factor: 5.469

9.  Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.

Authors:  A I Geller; A Freese
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

10.  Herpes simplex virus type 1 ICP27 is an essential regulatory protein.

Authors:  W R Sacks; C C Greene; D P Aschman; P A Schaffer
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  4 in total

1.  Gene delivery to rat enteric neurons using herpes simplex virus-based vectors.

Authors:  M K Howard; R S Coffin; A R Maclean; S M Brown; D Bailey; P N Anderson; G Burnstock; D S Latchman
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

Review 2.  Gene therapy for cancer: from the laboratory to the patient.

Authors:  G Kouraklis
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.487

3.  Antiangiogenic gene therapy of cancer: recent developments.

Authors:  Anita Tandle; Dan G Blazer; Steven K Libutti
Journal:  J Transl Med       Date:  2004-06-25       Impact factor: 5.531

Review 4.  Therapeutic Strategies for Neuropathic Pain: Potential Application of Pharmacosynthetics and Optogenetics.

Authors:  Gum Hwa Lee; Sang Seong Kim
Journal:  Mediators Inflamm       Date:  2016-01-13       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.